Manuel
Barreiro de Acosta
Hospital Royo Villanova
Zaragoza, EspañaPublications in collaboration with researchers from Hospital Royo Villanova (10)
2024
-
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 821-833
-
Efficacy and safety of biological treatment for inflammatory bowel disease in elderly patients: Results from a GETECCU cohort
Gastroenterologia y Hepatologia
-
Impact of mesalazine on the response to COVID-19 vaccination in patients with inflammatory bowel disease: Results of a prospective multicentre study of GETECCU (VACOVEII study)
Gastroenterologia y Hepatologia, Vol. 47, Núm. 7, pp. 750-758
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
2023
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2022
2021
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
2017
-
Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 12, pp. 1430-1439
2013
-
Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients
Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410